AstraZeneca and Daiichi Sankyo deepen ADC ambitions with Datroway’s TNBC approval
Datroway challenges chemotherapy in first-line TNBC. AstraZeneca and Daiichi Sankyo now face the real test: adoption, safety and access.
Pharma & Biotech
Pharma & Biotech
Could Agios and Avanzanite turn PYRUKYND into Europe’s next rare blood disease launch test?
PYRUKYND has EU approval in thalassaemia. Now Agios and Avanzanite face Europe’s harder test: access, uptake and reimbursement.
Medical Devices & Diagnostics
Can Inocras’ whole-genome HRD data change how ovarian cancer patients are selected for PARP maintenance?
PARP selection still leaves gaps. Inocras’ WGS-HRD data suggest whole-genome testing may refine ovarian cancer maintenance decisions.
Medical Devices & Diagnostics
Align Technology is betting $200m on Hyderabad. Here’s what changes next
Align needs growth and supply-chain efficiency. Its Hyderabad factory could turn India into a larger digital dentistry manufacturing base.
Pharma & Biotech
Why Galderma’s acne gel approval could quietly reset the over the counter dermatology market
Acne care is moving from prescription desks to retail shelves. Galderma’s Differin Epiduo switch tests how far OTC dermatology can go.
Pharma & Biotech
Why AstraZeneca’s EMERALD-3 and SERENA-6 data could influence future standards of cancer care
Could AstraZeneca’s latest ASCO 2026 cancer data reshape future treatment sequencing in liver and breast oncology? Read the full analysis.
Pharma & Biotech
How Gilead Sciences, Inc. could strengthen its liver disease franchise through Hepcludex commercialization
FDA approval of Hepcludex gives HDV its first U.S. therapy. Find out how this could reshape liver disease treatment and Gilead’s strategy.
Pharma & Biotech
Why Assembly Biosciences’ liver disease strategy now extends far beyond viral hepatitis
Assembly Biosciences is expanding ABI-6250 beyond HDV into PBC and PSC. Find out why NTCP inhibition is gaining industry attention.
Medical Devices & Diagnostics
Medtronic’s SPR Therapeutics deal signals a sharper move into earlier chronic pain intervention
Chronic pain care needs non-opioid options. Medtronic’s SPR Therapeutics deal tests whether temporary PNS can scale beyond niche adoption.
Medical Devices & Diagnostics
Why Donor Alliance and LifeSource are building a new model for transplant system performance
Organ donation needs trust and accountability. Vital Impact Health Group tests whether nonprofit OPO collaboration can raise transplant standards.